

Capecitabine and erlotinib in advanced lung cancer

Submission date 14/01/2015	Recruitment status No longer recruiting	☐ Prospectively registered ☐ Protocol
Registration date 23/01/2015	Overall study status Completed	☐ Statistical analysis plan ☒ Results
Last Edited 18/09/2017	Condition category Cancer	☐ Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr Mary E. R. O'Brien

Contact details
Royal Marsden NHS Foundation Trust
Downs Road
Sutton
Surrey
United Kingdom
SM2 5PT

Additional identifiers

Clinical Trials Information System (CTIS)
2008-007317-79

Protocol serial number
CCR3176

Study information

Scientific Title
A phase 1b trial of the combination of CApeCtabine and Tarceva in Advanced Lung Cancer

Acronym

CAPITAL

Study objectives

That the combination capecitabine and erlotinib is safe, tolerable, and active in patients with metastatic non-small cell lung cancer, to be considered for further testing in phase 2 clinical trials.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Regional Ethics Committee at the Royal Marsden NHS Foundation Trust, 16/10/2009, ref: 09/H0806/52

Primary study design

Interventional

Study design

Phase 1b clinical trial

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Metastatic non-small cell lung cancer with adenocarcinoma histology, in the second line setting

Interventions

Escalating doses of capecitabine (mg/sq.m, p.o., b.i.d.) and erlotinib (mg, p.o., daily) will be given on a 3-weekly cycle.

Intervention Type

Drug

Phase

Phase I

Drug/device/biological/vaccine name(s)

1. Capecitabine (Xeloda) 2. Erlotinib (Tarceva)

Primary outcome(s)

To determine the safety, tolerability and maximum tolerated dose of capecitabine when given in combination with erlotinib and to establish a dose limiting toxicity dose schedule for the combination.

Key secondary outcome(s)

Preliminary assessment of the efficacy of capecitabine when given in combination with erlotinib. Efficacy will be measured by assessment of response rates, progression-free survival, and overall survival.

Completion date

30/10/2014

Eligibility

Key inclusion criteria

1. Histologically confirmed diagnosis of NSCLC of adenocarcinoma sub-type. Mixed histological features are excluded
2. Progressing disease by radiological criteria
3. Any stage not fit for radical treatment
4. Age ≥ 18 years
5. ECOG performance status 0-2 and predicted life expectancy ≥ 12 weeks
6. Adequate haematopoietic, hepatic and renal function defined as follows: Absolute neutrophil count (ANC) $\geq 1.5 \times 10^9/L$ and platelet count $\geq 100 \times 10^9/L$ Bilirubin $\leq 1.5 \times ULN$, ALT (SGPT) $\leq 2.5 \times ULN$ (or $\leq 5 \times ULN$ in cases of liver metastases) Serum creatinine clearance ≥ 50 ml/min
7. Patients must provide verbal and written informed consent to participate in the study
8. Use of an acceptable contraception for men and women of childbearing potential

For part 1 of the protocol (2nd-line patients), all the general inclusion criteria (above) must be met. In addition the following must be met:

1. Previous treatment with systemic chemotherapy (one line only for non-adjuvant / radical treatment)
2. Recovery from any treatment related toxicities regardless of regimen prior to registration, except for alopecia, grade 2 fatigue, or grade 1 neurotoxicity

For part 2 of the protocol (1st-line patients), all the general inclusion criteria must be met. In addition the following must be met:

1. Unsuitable for platinum-based doublet chemotherapy

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 Years

Sex

All

Key exclusion criteria

1. Any concurrent anticancer systemic therapy
2. If the administration of erlotinib to patients receiving concomitant CYP3A4 or CYP1A2 inducers/inhibitors could impact significantly on their clinical care, these patients should be excluded- see Appendix 1
3. Prior treatment with any EGFR-directed inhibitor

4. Systemic chemotherapy, radiotherapy to a target lesion, or investigational anti-cancer treatment within 28 days of commencing treatment
5. Any other active malignancies unless deemed cured with at least 3 years of follow-up. In situ cervical cancer and in situ/basal cell skin cancer are permitted
6. Active or uncontrolled infections or serious illnesses or medical conditions that could interfere with the patients ongoing participation in the study
7. History of psychiatric condition that might impair the patients ability to understand or to comply with the requirements of the study or to provide informed consent
8. Gastro-intestinal abnormalities, including inability to take oral medication, requirement for intravenous feeding, active peptic ulcer, prior surgical procedures affecting absorption, any medical co-morbidity affecting gastrointestinal absorption
9. Patients on steroids must have been on that dose for at least 3 weeks
10. Pregnant women, or those currently breastfeeding

Date of first enrolment

18/03/2010

Date of final enrolment

28/10/2014

Locations

Countries of recruitment

United Kingdom

England

Study participating centre

Royal Marsden NHS Foundation Trust - Sutton

Downs Road

Sutton

Surrey

United Kingdom

SM2 5PT

Study participating centre

Royal Marsden NHS Foundation Trust

Fulham Road

Chelsea

London

United Kingdom

SW3 6JJ

Sponsor information

Organisation

Royal Marsden NHS Foundation Trust

ROR

<https://ror.org/0008wzh48>

Funder(s)**Funder type**

Industry

Funder Name

F Hoffman-La Roche Ltd (UK)

Results and Publications**Individual participant data (IPD) sharing plan****IPD sharing plan summary**

Not expected to be made available

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/02/2016		Yes	No
HRA research summary			28/06/2023	No	No